Seer (SEER) Non-Current Assets (2020 - 2026)
Seer (SEER) posted quarterly Non-Current Assets of $90.5 million for Q1 2026, down 1.58% year-over-year from $92.0 million in Q1 2025, and down 4.24% quarter-over-quarter from $94.5 million in Q4 2025.
Seer (SEER) Non-Current Assets (2020 - 2026) Analysis & Trends
Seer's Non-Current Assets history runs 7 years deep, the most recent figure standing at $90.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 1.58% year-over-year to $90.5 million; the TTM figure through Mar 2026 stood at $376.2 million (down 12.82% YoY), while the FY2025 annual figure was $94.5 million, down 16.53% from the prior year.
- Non-Current Assets for Q1 2026 stood at $90.5 million, down from $94.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $125.8 million in Q2 2023, with the low at $49.5 million in Q2 2022.
- The 5-year median for Non-Current Assets is $96.8 million (2025), against an average of $91.9 million.
- Peak annual rise in Non-Current Assets reached 640.58% in 2022, while the deepest fall reached 58.45% in 2022.
- Seer's Non-Current Assets stood at $52.9 million in 2022, then surged by 99.74% to $105.8 million in 2023, then advanced by 7.11% to $113.3 million in 2024, then retreated by 16.53% to $94.5 million in 2025, then retreated by 4.24% to $90.5 million in 2026.
- Business Quant data shows SEER's Non-Current Assets at $90.5 million in Q1 2026, $94.5 million in Q4 2025, and $94.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Seer | 230.63 Mn | 230.63 Mn | 1.51 Mn | 90.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.54 Mn |
| Mar 31, 2026 | 90.54 Mn |
| Dec 31, 2025 | 94.55 Mn |
| Sep 30, 2025 | 94.25 Mn |
| Jun 30, 2025 | 96.85 Mn |
| Mar 31, 2025 | 91.99 Mn |
| Dec 31, 2024 | 113.27 Mn |
| Sep 30, 2024 | 119.32 Mn |
| Jun 30, 2024 | 106.92 Mn |
| Mar 31, 2024 | 97.81 Mn |
| Dec 31, 2023 | 105.76 Mn |
| Sep 30, 2023 | 98.73 Mn |
| Jun 30, 2023 | 125.81 Mn |
| Mar 31, 2023 | 105.41 Mn |
| Dec 31, 2022 | 52.95 Mn |
| Sep 30, 2022 | 49.74 Mn |
| Jun 30, 2022 | 49.54 Mn |
| Mar 31, 2022 | 69.63 Mn |
| Dec 31, 2021 | 127.44 Mn |
| Sep 30, 2021 | 13.57 Mn |